Latest Biotech News

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.

The U.S. FDA has lifted the clinical hold on Neurizon Therapeutics’ lead drug candidate NUZ-001, enabling its entry into a major ALS platform trial set for Q4 2025. This regulatory milestone accelerates the company’s clinical development and opens doors for broader neurodegenerative applications.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.

Starpharma has entered a strategic research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary dendrimer technology, unlocking potential milestone payments of up to AUD $89 million.

Syntara Limited has reported positive final data from its Phase 2a trial of amsulostat in myelofibrosis, demonstrating significant symptom relief and spleen volume reduction with a favorable safety profile. These results pave the way for advancing clinical development and partnership discussions.

Syntara Limited has reported encouraging Phase 2a results for amsulostat combined with ruxolitinib in treating myelofibrosis, demonstrating sustained symptom improvement and spleen volume reduction over 52 weeks.

Bio-Gene Technology Limited has addressed ASX concerns over the timing of its announcement on promising Flavocide efficacy data, confirming compliance with continuous disclosure rules after receiving final presentation materials from Purdue University.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.